Skip to main content

Table 3 Cost-effectiveness results

From: Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme

Sensitivity analyses Screening No screening Incremental
Total Costs (m) Total QALYs Total Costs (m) Total QALYs Costs (m) 95% Confidence Interval (m) QALYs 95% Confidence Interval ICER
Base case £3.01 390 £6.44 307 -£3.04 (−£5.69, −£1.19) 82 (43, 139) Dominates
Incidence rate doubled £5.97 778 £12.88 614 -£6.50 (−£11.74, −£2.80) 164 (86, 277) Dominates
Incidence rate halved £1.51 194 £3.21 153 -£1.30 (−£2.62, −£0.39) 41 (22, 69) Dominates
CCALD 10% of total X-ALD £2.02 412 £2.21 397 £0.21 (−£0.06, £0.46) 16 (9, 24) £13,600
CCALD 15% of total X-ALD £2.13 409 £2.70 386 -£0.17 (−£0.63, £0.22) 23 (14, 36) Dominates
CCALD 60% HSCT rate £5.20 340 £6.41 307 -£0.81 (−£2.01, £0.02) 33 (15, 60) Dominates
CCALD 10% of total X-ALD and 80% HSCT rate £2.23 407 £2.21 396 £0.42 (£0.24, £0.62) 11 (6, 17) £38,701
CCALD 15% of total X-ALD and 80% HSCT rate £2.43 401 £2.69 385 £0.15 (−£0.18, £0.42) 16 (9, 26) £8927
CCALD 20% of total X-ALD and 80% HSCT rate £2.65 396 £3.18 375 -£0.12 (−£0.59, £0.24) 22 (13, 34) Dominates
1.5% Discount Rate £4.59 611 £9.35 455 -£4.36 (−£7.97, −£1.81) 156 (83, 260) Dominates
Both girls and boys screened £3.27 800 £6.96 718 -£3.27 (−£5.97, −£1.36) 82 (43, 139) Dominates
  1. m million